title: "Rhabdoid" meningioma: an aggressive variant.
abstract: It is has been suggested that rhabdoid morphology is associated with a poor prognosis, regardless of tumor histogenesis. We report a series of 15 meningiomas with rhabdoid features. Nine patients had undergone multiple resections. In six, the rhabdoid component was histologically apparent only in recurrences. Rhabdoid morphology was defined as sheets of loosely cohesive cells with eccentric nuclei and hyaline, paranuclear inclusions. Ultrastructurally, the latter consisted of whorls of intermediate filaments often entrapping lysosomes or other organelles. Meningothelial features included whorl formation and nuclear pseudoinclusions, immunohistochemical coexpression of vimentin and epithelial membrane antigen, and the ultrastructural finding of interdigitating cell membranes and intercellular junctions. At the histologic level, a conventional meningioma component was noted in most tumors; only four lesions were entirely rhabdoid. Histologic malignancy (brain invasion or anaplasia) was observed in nine cases, another two tumors being considered malignant on the basis of extracranial metastasis. In the majority, increased cell proliferation was evidenced by a high mitotic rate or MIB-1 LI. At last follow-up, 13 patients (87%) had experienced at least one recurrence and 8 (53%) were dead of disease. Median time to death was 5.8 years after initial surgery and 3.1 years after the first appearance of rhabdoid morphology. Our findings corroborate those from a smaller series recently reported by Kepes et al. on the same entity (Kepes JJ, Moral LA, Wilkinson SB, Abdullah A, Llena JF. Rhabdoid transformation of tumor cells in meningiomas: A histologic indication of increased proliferative activity. Report of four cases. Am J Surg Pathol 1998;22:231-8). They further suggest that rhabdoid meningiomas are highly aggressive tumors and that the rhabdoid phenotype represents a marker of malignant transformation in meningiomas.
authors.affiliation: Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. aperry@pathology.wustl.edu
authors.forename: A
authors.initials: A
authors.lastname: Perry
authors.forename: B W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: S L
authors.initials: SL
authors.lastname: Stafford
authors.forename: P C
authors.initials: PC
authors.lastname: Abell-Aleff
authors.forename: F B
authors.initials: FB
authors.lastname: Meyer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D002479:Inclusion Bodies / Q000648:ultrastructure; D008297:Male; D008577:Meningeal Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008579:Meningioma / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008875:Middle Aged; D008940:Mitotic Index; D018396:Mucin-1 / Q000378:metabolism; D015388:Organelles / Q000648:ultrastructure; D018335:Rhabdoid Tumor / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D014746:Vimentin / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D018396:Mucin-1; D014746:Vimentin